RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 109-116

  Chen, Yangchao ^a   Xie, Dan ^b   Yin Li, Wing ^a   Man Cheung, Chi ^a   Yao, Hong ^a   Chan, Ching Yu ^a   Chan, Chu yan ^a   Xu, Fang Ping ^c   Liu, Yan Hui ^c   Sung, Joseph J Y ^a   Kung, Hsiang Fu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Enhancer of zeste homolog 2; Liver metastasis; Pancreatic cancer; Tumorigenecity

Indexed keywords

TRANSCRIPTION FACTOR EZH2; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; TISSUE MICROARRAY; ANIMAL; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; DRUG SCREENING; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; SECONDARY; TIME; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ADULT; AGED; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; GENETIC THERAPY; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 77956231521     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.003     Document Type: Article

References (40)

1. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001, 37(Suppl 8):S4-66.
2. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Data Base report on pancreatic cancer. Cancer 1995, 76:1671-1677.
3. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 1999, 189:1-7.
4. Real F.X. A " catastrophic hypothesis" for pancreas cancer progression. Gastroenterology 2003, 124:1958-1964.
5. Nakao A., Fujii T., Sugimoto H., Kanazumi N., Nomoto S., Kodera Y., et al. Oncological problems in pancreatic cancer surgery. World J. Gastroenterol. 2006, 12:4466-4472.
6. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia, neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer 2003, 2:12.
7. Porta M., Fabregat X., Malats N., Guarner L., Carrato A., de Miguel A., et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin. Trans. Oncol. 2005, 7:189-197.
8. Wade T.P., Halaby I.A., Stapleton D.R., Virgo K.S., Johnson F.E. Population-based analysis of treatment of pancreatic cancer and Whipple resection: department of defense hospitals 1989-1994. Surgery 1996, 120:680-685. (discussion 6-7).
9. Masui T., Hosotani R., Ito D., Virgo K.S., Johnson F.E. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer. Surgery 2006, 140:149-160.
10. Reni M., Pasetto L., Aprile G., Cordio S., Bonetto E., Dell'Oro S., et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Brit. J. Cancer 2006, 94:785-791.
11. Caldas C., Aparicio S. Cell memory and cancer - the story of the trithorax and polycomb group genes. Cancer Metast. Rev. 1999, 18:313-329.
12. Muyrers-Chen I., Paro R. Epigenetics: unforeseen regulators in cancer. Biochim. Biophys. Acta 2001, 1552:15-26.
13. Francis N.J., Saurin A.J., Shao Z., Kingston R.E. Reconstitution of a functional core polycomb repressive complex. Mol. Cell 2001, 8:545-556.
14. Sewalt R.G., van der Vlag J., Gunster M.J., Hamer K.M., den Blaauwen J.L., Satijn D.P., et al. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol. Cell. Biol. 1998, 18:3586-3595.
15. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043.
16. Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002, 16:2893-2905.
17. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
18. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
19. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., Manders E.M., Raaphorst F.M., Meijer C.J., et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Brit. J. Haematol. 2001, 112:950-958.
20. Steele J.C., Torr E.E., Noakes K.L., Kalk E., Moss P.A., Reynolds G.M., et al. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Brit. J. Cancer 2006, 95:1202-1211.
21. Chen Y., Lin M.C., Wang H., Chan C.Y., Jiang L., Ngai S.M., et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 2007, 7:3097-3104.
22. Chen Y., Lin M.C., Yao H., Wang H., Zhang A.Q., Yu J., et al. Lentivirus-mediated RNA interference targeting EZH2 inhibits hepatocellular carcinoma growth via down-regulation of stathmin. Hepatology 2007, 46:200-208.
23. Xie D., Sham J.S., Zeng W.F., Lin H.L., Bi J., Che L.H., et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Human Pathol. 2005, 36:777-783.
24. Xie D., Lau S.H., Sham J.S., Wu Q.L., Fang Y., Liang L.Z., et al. Upregulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005, 103:277-283.
25. Chen Y., Stamatoyannopoulos G., Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003, 63:4801-4804.
26. Kuruppu D., Christophi C., Bertram J.F., O'Brien P.E. Characterization of an animal model of hepatic metastasis. J. Gastroenterol. Hepatol. 1996, 11:26-32.
27. Sasaki M., Yamaguchi J., Itatsu K., Ikeda H., Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 2008, 215:175-183.
28. Fujii S., Ito K., Ito Y., Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 2008, 283:17324-17332.
29. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin. Cancer Res. 2008, 14:6790-6796.
30. Mok T.S., Leung T.W. Changes in chemotherapy for pancreatic cancer. Hong Kong Med. J. 1999, 5:367-374.
31. Shi X., Liu S., Kleeff J., Friess H., Büchler M.W. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62:354-362.
32. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
33. Westerdahl J., Andren-Sandberg A., Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic?. Hepatogastroenterology 1993, 40:384-387.
34. Block A., Chen S.H., Kosai K., Finegold M., Woo S.L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997, 15:25-34.
35. Takeuchi M M., Shichinohe T., Senmaru N., Miyamoto M., Fujita H., Takimoto M., et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther. 2000, 7:518-526.
36. Murakami M., Nagai E., Mizumoto K., Saimura M., Ohuchida K., Inadome N., et al. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int. J. Cancer 2005, 117:160-165.
37. Lu Y., Bai J.G., Wang H.H. Gene therapeutic treatment of pancreatic cancer based on injection of pcDNA3.1/CCK plasmid with xenogeneic homologous cholecystokinin. Exp. Oncol. 2006, 28:136-140.
38. Himeno Y., Etoh T., Matsumoto T., Ohta M., Nishizono A., Kitano S. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int. J. Oncol. 2005, 27:901-906.
39. Noro T., Miyake K., Suzuki-Miyake N., Igarashi T., Uchida E., Misawa T., et al. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res. 2004, 64:7486-7490.
40. Bloomston M., Shafii A., Zervos E.E., Rosemurgy A.S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res. 2002, 102:39-44.